TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Transcenta, Biologics, Antibody, Claudin 18.2

TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Careers Contact
背景
Target:
Claudin 18.2
Indication:
G/GEJC/PDAC
Project Status:
Phase III

Osemitamab (TST001) is the second most advanced Claudin18.2 targeting antibody therapeutic candidate being developed globally. It is generated by using Transcenta's Immune Tolerance Breaking Technology (IMTB) platform.

 

Osemitamab (TST001) has high affinity, and enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

 

Since August 2020, clinical trials for Osemitamab (TST001) are ongoing in China and US  (NCT05190575, NCT04396821, NCT04495296, NCT05608785 / CTR20201281). Osemitamab (TST001) was granted Orphan Drug Designation in the US by FDA for the treatment of patients with gastric cancer or gastroesophageal junction (GC/GEJ) and pancreatic cancer


微信截图_20230823151247.png

Mechanism of Action

Claudin18.2 is a transmembrane protein highly expressed in multiple solid tumor cells. In normal tissues, the expression of Claudin18.2 is restricted to the differentiated epithelial cells of the stomach. The high tissue specificity and tumor specificity makes Claudin18.2 an extremely promising target for next-generation targeted therapy.

 

Osemitamab (TST001) kills Claudin18.2 expressing tumor cells by mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Leveraging advanced bioprocessing technology, the fucose content of Osemitamab (TST001) was significantly reduced during the production, which further enhanced NK cells mediated ADCC activity of Osemitamab (TST001).


Ongoing Clinical Trials
TOP